JP2024511024A5 - - Google Patents
Info
- Publication number
- JP2024511024A5 JP2024511024A5 JP2023557013A JP2023557013A JP2024511024A5 JP 2024511024 A5 JP2024511024 A5 JP 2024511024A5 JP 2023557013 A JP2023557013 A JP 2023557013A JP 2023557013 A JP2023557013 A JP 2023557013A JP 2024511024 A5 JP2024511024 A5 JP 2024511024A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- item
- adrenal
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163634P | 2021-03-19 | 2021-03-19 | |
| US63/163,634 | 2021-03-19 | ||
| PCT/US2022/020933 WO2022198038A1 (en) | 2021-03-19 | 2022-03-18 | Gene therapies for 21-hydroxylase deficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511024A JP2024511024A (ja) | 2024-03-12 |
| JP2024511024A5 true JP2024511024A5 (https=) | 2025-02-04 |
Family
ID=81308190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557013A Pending JP2024511024A (ja) | 2021-03-19 | 2022-03-18 | ２１－ヒドロキシラーゼ欠損症の遺伝子治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240191213A1 (https=) |
| EP (1) | EP4308711A1 (https=) |
| JP (1) | JP2024511024A (https=) |
| KR (1) | KR20230159837A (https=) |
| AR (1) | AR125143A1 (https=) |
| BR (1) | BR112023018430A2 (https=) |
| CA (1) | CA3212876A1 (https=) |
| WO (1) | WO2022198038A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3088323A1 (en) | 2018-01-17 | 2019-07-25 | Adrenas Therapeutics, Inc. | Adeno-associated virus gene therapy for 21-hydroxylase deficiency |
| CN116350801A (zh) * | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| AU2024317892A1 (en) * | 2023-07-29 | 2025-08-28 | Limited Liability Company «Genetic Technologies» (Llc «Genetic Technologies») | Adeno-associated virus-based expression vectors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| DK2573170T3 (en) | 2001-12-17 | 2018-04-09 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| IL297919A (en) | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
| CA3088323A1 (en) | 2018-01-17 | 2019-07-25 | Adrenas Therapeutics, Inc. | Adeno-associated virus gene therapy for 21-hydroxylase deficiency |
-
2022
- 2022-03-18 WO PCT/US2022/020933 patent/WO2022198038A1/en not_active Ceased
- 2022-03-18 BR BR112023018430A patent/BR112023018430A2/pt unknown
- 2022-03-18 AR ARP220100635A patent/AR125143A1/es unknown
- 2022-03-18 KR KR1020237034360A patent/KR20230159837A/ko active Pending
- 2022-03-18 US US18/551,143 patent/US20240191213A1/en active Pending
- 2022-03-18 EP EP22716616.2A patent/EP4308711A1/en active Pending
- 2022-03-18 CA CA3212876A patent/CA3212876A1/en active Pending
- 2022-03-18 JP JP2023557013A patent/JP2024511024A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024511024A5 (https=) | ||
| CN109069672B (zh) | 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症 | |
| JP2021087431A5 (https=) | ||
| JP7541027B2 (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| JP2022547197A5 (https=) | ||
| JP2023514242A5 (https=) | ||
| US20060239972A1 (en) | Adiponectin gene therapy | |
| US20020076754A1 (en) | Overcoming AAV vector size limitation through viral DNA hetero-dimerization | |
| CN114231532B (zh) | 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用 | |
| JP2021511020A5 (https=) | ||
| JP2024511024A (ja) | ２１－ヒドロキシラーゼ欠損症の遺伝子治療 | |
| US20230175015A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| US20060188482A1 (en) | Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal | |
| JP2025124694A (ja) | Ｉｇｈｍｂｐ２遺伝子に関連する障害の治療のための材料および方法 | |
| JP2024505885A (ja) | リソソーム酸リパーゼ欠損症（ｌａｌ－ｄ）の治療のための材料及び方法 | |
| AU2021340584A9 (en) | Systemic delivery of adeno-associated virus vector expressing g-sarcoglycan and the treatment of muscular dystrophy | |
| EP4724589A1 (en) | Gene therapy for lysosomal acid lipase deficiency (lal-d) | |
| JP7826334B2 (ja) | 髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルス | |
| JP2025534651A (ja) | 呼吸困難を伴う脊髄性筋萎縮１型（ｓｍａｒｄ１）及びシャルコー・マリー・トゥース２ｓ型（ｃｍｔ２ｓ）を治療するためのアデノ随伴ウイルス送達 | |
| HK40118571A (zh) | 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症 | |
| BR122024002143A2 (pt) | Vetor de aavrh7.4 recombinante, composição, uso dos mesmos e método para produzir uma proteína micro-distrofina funcional | |
| BR122025027836A2 (pt) | Vetor de aavrh7.4 recombinante, composição, uso dos mesmos e método para produzir uma proteína micro-distrofina funcional |